Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells.

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA.

Mol Cancer Res. 2019 Aug 8. doi: 10.1158/1541-7786.MCR-18-0605. [Epub ahead of print]

PMID:
31395667
2.

Role of serum response factor expression in prostate cancer biochemical recurrence.

Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW.

Prostate. 2018 Jul;78(10):724-730. doi: 10.1002/pros.23516. Epub 2018 Apr 2.

PMID:
29608018
3.

Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB.

Br J Cancer. 2018 Mar 20;118(6):e11. doi: 10.1038/bjc.2017.470. Epub 2018 Feb 20.

4.

Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB.

Br J Cancer. 2017 Nov 21;117(11):1656-1664. doi: 10.1038/bjc.2017.346. Epub 2017 Oct 3. Erratum in: Br J Cancer. 2018 Feb 20;:.

5.

Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness.

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS.

Urol Oncol. 2017 Mar;35(3):111.e1-111.e8. doi: 10.1016/j.urolonc.2016.10.002. Epub 2016 Nov 9.

PMID:
27838142
6.

PBX3 is a putative biomarker of aggressive prostate cancer.

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA.

Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25.

7.

Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA.

Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479.

8.

β-Adrenergic Receptor Signaling in Prostate Cancer.

Braadland PR, Ramberg H, Grytli HH, Taskén KA.

Front Oncol. 2015 Jan 12;4:375. doi: 10.3389/fonc.2014.00375. eCollection 2014. Review.

10.

Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA.

Eur Urol. 2014 Mar;65(3):635-41. doi: 10.1016/j.eururo.2013.01.007. Epub 2013 Jan 14.

PMID:
23351721
11.

Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL.

Prostate. 2013 Feb 15;73(3):250-60. doi: 10.1002/pros.22564. Epub 2012 Jul 20.

PMID:
22821802

Supplemental Content

Loading ...
Support Center